Search
Edwards Lifesciences Corp
EWAdd to Watchlist
86.960USD
+1.080+1.26%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
50.18BMarket Cap
46.18P/E TTM
More Details of Edwards Lifesciences Corp Company
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Edwards Lifesciences Corp Info
Ticker SymbolEW
Company nameEdwards Lifesciences Corp
IPO dateMar 27, 2000
CEOZovighian (Bernard J)
Number of employees15800
Security typeOrdinary Share
Fiscal year-endMar 27
AddressOne Edwards Way
CityIRVINE
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code92614
Phone19492502500
Websitehttps://www.edwards.com
Ticker SymbolEW
IPO dateMar 27, 2000
CEOZovighian (Bernard J)
Company Executives of Edwards Lifesciences Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
284.40K
+2.48%
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
79.69K
+5.41%
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
39.67K
+16.33%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
30.12K
+59.32%
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
22.62K
+53.60%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.56K
+58.48%
Mr. Donald E. Bobo, Jr.
Mr. Donald E. Bobo, Jr.
Corporate Vice President - Strategy and Corporate Development
Corporate Vice President - Strategy and Corporate Development
--
--
Mr. Nicholas J. (Nick) Valeriani
Mr. Nicholas J. (Nick) Valeriani
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kieran T. Gallahue
Mr. Kieran T. Gallahue
Independent Director
Independent Director
--
--
Ms. Leslie S. Heisz
Ms. Leslie S. Heisz
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
284.40K
+2.48%
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
79.69K
+5.41%
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
39.67K
+16.33%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
30.12K
+59.32%
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
22.62K
+53.60%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.56K
+58.48%
FAQs
Who are the top five shareholders of Edwards Lifesciences Corp?
The top five shareholders of Edwards Lifesciences Corp are: Mr. Scott B. Ullem
How many institutions hold shares of Edwards Lifesciences Corp (EW)?
As of 2026Q1, 2620 institutions hold shares of Edwards Lifesciences Corp, with a combined market value of approximately 539.60M, accounting for 93.71% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -12944884.00.
What is the biggest source of revenue for Edwards Lifesciences Corp?
In 2026Q1, the Transcatheter Aortic Valve Replacement business generated the highest revenue for Edwards Lifesciences Corp, amounting to 4.49B and accounting for 73.96% of total revenue.
